Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Deals

Video: Sean Marett On BioNTech's Immunotherapy Alliance With Sanofi

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company COO Marett reviews BioNTech's RNA technology and the potential for immunotherapy combination studies, on the sidelines of BIO-Europe 2015.

MUNICH – BioNTech AG Chief Operating Officer Sean Marett discusses his company's recent immunotherapy deal with Sanofi [See Deal], in an interview with Mike Ward, Informa Pharma Insights global director of content, at BIO-Europe 2015. ("The Pink Sheet" DAILY is part of Informa Pharma Insights.) The two talk about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies.

BIO-Europe 2015

Interview With Sean Marett

Look for more BIO-Europe exclusive interviews in the next few days at "The Pink Sheet" DAILY. To see more video interviews and panel discussions from BIO-Europe 2015 visit Partnering360.

Table

View full table

Topics

Related Companies

Related Deals

Tags:
BioPharmaceutical Deals
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS078027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By